Galena Biopharma Says FBP Vaccine Is Safe, Immunogenic - Quick Facts

(RTTNews) - Galena Biopharma (GALE), said phase 1 trial results of Folate Binding Protein or FBP vaccine showed it is both safe and immunogenic. The company announced a poster presentation of the same at the Society for Immunotherapy of Cancer Conference. The primary outcome of the trial was to determine safety and the optimal dose, with a secondary outcome to look for an initial efficacy signal and immunological response.

FBP is a folate receptor alpha-derived, peptide-based cancer immunotherapy administered to HLA A2 positive patients in combination with granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant treatment to prevent recurrences in high-risk, endometrial and ovarian cancer patients rendered disease-free after completing standard of care therapy.

Looking forward, the company said: "As a result, we are moving forward with the Phase 2a component which will be initiated by year end and will include the enrollment of additional patients at the optimal dose as well implementing a booster regimen."